Findings

What do systematic reviews say?

1,017 questions · 1,061 findings · 131 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 193 · 18.2%GRADE not reported 65 · 6.1%Very low 237 · 22.3%Low 325 · 30.6%Moderate 187 · 17.6%High 54 · 5.1%

IVIg vs placebo

Response at 3 months · adults with renal vasculitis

Intravenous immunoglobulin may leads to higher response at 3 months compared with placebo (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 2.33 [1.18, 4.61]
1 study · 34 participants
Low

IVIg vs placebo

Relapse at 3 months · adults with renal vasculitis

Intravenous immunoglobulin showed no clear difference in relapse at 3 months compared with placebo (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.17 [0.39, 3.56]
1 study · 34 participants
Low

IVIg vs placebo

Adverse events · adults with renal vasculitis

Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 3
1 study · 34 participants
Low

IVIg vs placebo

Serious infection · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intravenous acetylcysteine vs placebo

All‐cause mortality · people with fulminant hepatic failure secondary to paracetamol (acetaminophen) overdose

Intravenous acetylcysteine may leads to lower mortality compared with placebo (low certainty).

1 finding from 1 review

Interventions for paracetamol (acetaminophen) overdose 2018 · Cochrane Headline outcomes only
Peto OR 0.29 [0.09, 0.94]
1 study · 50 participants
Low

IVIg vs placebo

SAEs · NSTI

Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 0.73 [0.32, 1.65]
1 study · 100 participants
Low

IVIg vs placebo

Survival time · NSTI

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Low

IVIg vs placebo

Assessment of long‐term morbidity · NSTI

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

All‐cause mortality · NSTI

Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 1.17 [0.42, 3.23]
1 study · 100 participants
Low

IVIg vs placebo

Muscle strength · people with inclusion body myositis

2 findings from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 78 participants
GRADE not reported
Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

Significant adverse events · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 78 participants
GRADE not reported

Intravenous tranexamic acid vs placebo

Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures

Intravenous tranexamic acid may leads to lower risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes only
RR 0.48 [0.34, 0.69]
6 studies · 457 participants
Low

Intravenous tranexamic acid vs placebo

All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures

Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes only
Peto OR 0.38 [0.05, 2.77]
2 studies · 147 participants
Low

Intravenous tranexamic acid vs placebo

Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intravenous tranexamic acid vs placebo

Myocardial infarction (0 to 30 days) · people undergoing definitive fixation of hip, pelvic and long bone fractures

Intravenous tranexamic acid showed no clear difference in risk of myocardial infarction (30 days post‐surgery) compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes only
RD 0
2 studies · 199 participants
Low

Intravenous tranexamic acid vs placebo

Stroke · people undergoing definitive fixation of hip, pelvic and long bone fractures

Intravenous tranexamic acid showed no clear difference in risk of cerebrovascular accident/stroke (30 days post‐surgery) compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes only
RD 0
3 studies · 324 participants
Low

Intravenous tranexamic acid vs placebo

Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures

It is very uncertain whether intravenous tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes only
Peto OR 2.15 [0.22, 21.35]
4 studies · 329 participants
Very low